These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease? Taymans JM Expert Opin Ther Pat; 2014 Jul; 24(7):727-30. PubMed ID: 24875782 [TBL] [Abstract][Full Text] [Related]
25. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998 [TBL] [Abstract][Full Text] [Related]
26. Unveiling the Selectivity Mechanism of Type-I LRRK2 Inhibitors by Computational Methods: Insights from Binding Thermodynamics and Kinetics Simulation. Tan S; Wang J; Gao P; Xie G; Zhang Q; Liu H; Yao X ACS Chem Neurosci; 2023 Sep; 14(18):3472-3486. PubMed ID: 37647597 [TBL] [Abstract][Full Text] [Related]
28. In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2. Vancraenenbroeck R; De Raeymaecker J; Lobbestael E; Gao F; De Maeyer M; Voet A; Baekelandt V; Taymans JM Front Mol Neurosci; 2014; 7():51. PubMed ID: 24917786 [TBL] [Abstract][Full Text] [Related]
29. A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls. Vissers MFJM; Troyer MD; Thijssen E; Pereira DR; Heuberger JAAC; Groeneveld GJ; Huntwork-Rodriguez S Clin Transl Sci; 2023 Aug; 16(8):1408-1420. PubMed ID: 37177855 [TBL] [Abstract][Full Text] [Related]
30. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons. Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152 [TBL] [Abstract][Full Text] [Related]
31. Multi-method computational evaluation of the inhibitors against leucine-rich repeat kinase 2 G2019S mutant for Parkinson's disease. Elhadi A; Zhao D; Ali N; Sun F; Zhong S Mol Divers; 2024 Feb; ():. PubMed ID: 38396210 [TBL] [Abstract][Full Text] [Related]
32. LRRK2 Inhibition Mitigates the Neuroinflammation Caused by TLR2-Specific α-Synuclein and Alleviates Neuroinflammation-Derived Dopaminergic Neuronal Loss. Ho DH; Nam D; Seo M; Park SW; Seol W; Son I Cells; 2022 Mar; 11(5):. PubMed ID: 35269482 [TBL] [Abstract][Full Text] [Related]
33. LRRK2-NFATc2 Pathway Associated with Neuroinflammation May Be a Potential Therapeutic Target for Parkinson's Disease. Wang Y; Zhang X; Chen F; Chen L; Wang J; Xie J J Inflamm Res; 2021; 14():2583-2586. PubMed ID: 34168481 [TBL] [Abstract][Full Text] [Related]
34. LRRK2 G2019S Induces Anxiety/Depression-like Behavior before the Onset of Motor Dysfunction with 5-HT Lim J; Bang Y; Choi JH; Han A; Kwon MS; Liu KH; Choi HJ J Neurosci; 2018 Feb; 38(7):1611-1621. PubMed ID: 29305532 [TBL] [Abstract][Full Text] [Related]
35. Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade. Thakur G; Kumar V; Lee KW; Won C Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011337 [TBL] [Abstract][Full Text] [Related]
37. Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives. Hu J; Zhang D; Tian K; Ren C; Li H; Lin C; Huang X; Liu J; Mao W; Zhang J Eur J Med Chem; 2023 Aug; 256():115475. PubMed ID: 37201428 [TBL] [Abstract][Full Text] [Related]
38. The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease. Tang X; Xing S; Ma M; Xu Z; Guan Q; Chen Y; Feng F; Liu W; Chen T; Chen Y; Sun H J Med Chem; 2023 Feb; 66(4):2282-2307. PubMed ID: 36758171 [TBL] [Abstract][Full Text] [Related]
39. Alternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease. Koshibu K; van Asperen J; Gerets H; Garcia-Ladona J; Lorthioir O; Courade JP Pharmacology; 2015; 96(5-6):240-7. PubMed ID: 26382237 [TBL] [Abstract][Full Text] [Related]
40. Identification of high-affinity inhibitors of pyruvate dehydrogenase kinase-3: towards therapeutic management of cancer. Mohammad T; Arif K; Alajmi MF; Hussain A; Islam A; Rehman MT; Hassan I J Biomol Struct Dyn; 2021 Feb; 39(2):586-594. PubMed ID: 31903847 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]